FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCL

The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Interim Analysis for Phase Ib Study of Resiniferatoxin Generates Positive Data

An interim analysis of the ongoing phase Ib study of resiniferatoxin, administered via epidural route in patients with intractable cancer pain, has produced positive data.

Blood Test Predicts Clinical Response to Immunotherapy in Metastatic NSCLC

Researchers suggested that patients with non-small cell lung cancer (NSCLC) who have higher measures of tumor mutations that appear in a blood test generally have a better clinical response to PD-1-based immunotherapy than those with a lower measure of mutations.